The Stockholm CREAtinine Measurements Project

NCT06239129 | Completed FDA Drug

• 1 other identifier: 000001
• Study Type: observational
• Target: 3,200,000
• Locations: 0 countries
• Sites: N/A

Brief Summary

The Stockholm CREAtinine Measurements (SCREAM) project is a healthcare utilization cohort including, at present, all adult residents in Stockholm between 2006 and 2021. The region of Stockholm had a population of 2.3 million citizens in 2021and provides universal healthcare with a single unified health-system. Administrative databases with complete information on socidemographic data, healthcare use, diagnoses and therapeutic/surgical procedures, and vital status were enriched with performed laboratory tests, dispensed prescriptions at Swedish pharmacies and validated kidney replacement therapy endpoints. Registries were linked and de-identified by the Swedish National Board of Welfare and are considered to have no or minimal loss to follow-up. Because the study utilized de-identified data, it was deemed not to require informed consent and was approved by the regional ethical review boards and the Swedish National Board of Welfare. For detailed description of available data and linked registers please consult: https://pubmed.ncbi.nlm.nih.gov/35028991/

Conditions

Chronic Kidney Diseases; Acute Kidney Injury; Diabetes Mellitus; Cardiovascular Diseases; Hypertension

Outcome Measures

Primary Outcomes (3)

• Adverse health events by levels of kidney function

  multiple outcomes evaluated such as cardiovascular events, fractures, dementia, cancer, etc, all of them based on claims data and/or laboratory data

  2006-2021

• Safety and efficacy of medications by levels of kidney function

  multiple outcomes evaluated depending on the treatments of interest, all of them based on claims data and/or laboratory data

  2006-2021

• Effect of medications or conditions on kidney function decline

  Evaluation of changes in kidney function over time upon occurrence of a certain condition (i.e., heart failure or covid19 infection) or initiation of a specific medication

  2006-2021

Secondary Outcomes (1)

• Adverse health events associated to laboratory abnormalities

  2006-2021

Interventions

Initiation of specific medications DRUG

multiple therapies studied within this database

Also known as: multiple therapies studied within this database

Undertaking of specific procedures PROCEDURE

multiple procedures/surgeries studied within this database

Abnormalities in specific laboratory tests DIAGNOSTIC_TEST

multiple abnormalities in laboratory values (i.e. CRP, cholesterol, eGFR, potassium) studied within this database

Eligibility Criteria

• Age: 0 Years - 110 Years
• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Stockholm residents with/without ever testing for creatinine or albumuninuria

You may qualify if:

• For both cohorts:
• Be a resident of Stockholm during 2006-2021, of all ages
• For the primary cohort:
• To have undertaken at least one test of serum creatinine or albuminuria during 2006-2021. If this condition is met, we will then extract a broad range of laboratory tests
• For the secondary cohort:
• Anyone not undertaking a test of serum creatinine or albuminuria will conform the secondary cohort. In this cohort we will not extract any other laboratory test, but will obtain the rest of healthcare information

You may not qualify if:

• None

Sponsors & Collaborators

• Karolinska Institutet: lead
• Region Stockholm: collaborator

Related Publications (1)

• Russel WA, Fu EL, Bosi A, Caldinelli A, Inker LA, Chang AR, Levey AS, Carrero JJ. Obesity, Underweight, and Accuracy of eGFR Using Cystatin C and Creatinine in a Northern European Population. J Am Soc Nephrol. 2025 Nov 1;36(11):2177-2189. doi: 10.1681/ASN.0000000760. Epub 2025 Jun 13.

  PMID: 40512561 DERIVED

MeSH Terms

Conditions

Renal Insufficiency, Chronic; Acute Kidney Injury; Diabetes Mellitus; Cardiovascular Diseases; Hypertension

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Vascular Diseases

Study Officials

• Juan J Carrero, Prof

  Karolinska Institutet

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 15 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Cardiorenal Epidemiology

Study Record Dates

• First Submitted: January 17, 2024
• First Posted: February 2, 2024
• Study Start: January 1, 2006
• Primary Completion: December 31, 2021
• Study Completion: December 31, 2022
• Last Updated: February 2, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
• Time Frame: For the time required to perform the collaborative project
• Access Criteria: Primarily by welcoming researchers to analyse the data physically in Stockholm. Exceptionally by opening secure VDI connections to work under our online servers